Stability of infliximab dosing in inflammatory bowel disease: Results from a multicenter US chart review

Journal of Medical Economics

Volumn 14, Issue 4, 2011, Pages 397-402

  Waters, Heidi ^a,b   Vanderpoel, Julie ^a   McKenzie, Scott ^a   Lunacsek, Orsolya ^c   Franklin, Meg ^d   Lennert, Barbara ^c   Goff, John ^e   Augustyn, Damian H ^f  

^a CENTOCOR INC   (United States)

^b ETHICON INC   (United States)

^c XCENDA   (United States)

^d PRESBYTERIAN COLLEGE   (United States)

^e Rocky Mountain Gastroenterology Associates PLLC   (United States)

^f Pacific Internal Medicine   (United States)

Author keywords

Anti tumor necrosis factor therapy; Crohns disease; Inflammatory bowel disease; Infliximab; Ulcerative colitis

Indexed keywords

INFLIXIMAB;

ARTICLE; BODY WEIGHT; CROHN DISEASE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; HUMAN; MAINTENANCE DRUG DOSE; MEDICAL RECORD REVIEW; MULTICENTER STUDY; ULCERATIVE COLITIS; UNITED STATES; UNSPECIFIED SIDE EFFECT;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 79960147692     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2011.583152     Document Type: Article

References (31)

1. Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 2006;12:s3-9 (Pubitemid 43068428)
2. DiPiro JT, Schade RR. Inflammatory bowel disease. In: DiPiro JT, Talbert RL, Yee GC, et al. Pharmacotherapy: a Pathophysiologic Approach, 6th edn. New York: McGraw-Hill, 2005:1007-21
3. Canavan C, Abrams KR, Mayberry JF. Meta-analysis: mortality in Crohns disease. Ailment Pharmacol Ther 2007;25:861-70
4. Feagan BG, Vreeland MG, Larson LR, et al. Annual cost of care for Crohns disease: a payor perspective. Am J Gastroenterol 2000;95:1955-60
5. Pohl C, Hombach A, Kruis W. Chronic inflammatory bowel disease and cancer. Hepatogastroenterology 2000;47:57-70 (Pubitemid 30085390)
6. Roifman I, Sun YC, Fedwick JP, et al. Evidence of endothelial dysfunction in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2009;7:175-82
7. Hanauer SB. Medical management of Crohns disease: treatment algorithms Dig Dis 2009;27:536-41
8. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010;105;501-23
9. Lichtenstein GR, Hanauer SB, Sandborn WJ, and the Practice Parameters Committee of the American College of Gastroenterology. Management of Crohns disease in adults. Am J Gastroenterol 2009;104:465-83
10. Cury DB, Cury MS, Elias GVH, et al. Infliximab to treat severe ulcerative colitis. World J Gastroenterol 2009;15:1771-3
11. Hanauer SB, Feagan BG, Lichtenstein GR, et al. and the ACCENT I Study Group. Maintenance infliximab for Crohns disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9 (Pubitemid 34621118)
12. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohns disease: TREAT registry. Clin Gastroenterol Hepatol 2006;4:621-30
13. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohns disease. N Engl J Med 1999;340:1398-405 (Pubitemid 29205403)
14. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76 (Pubitemid 41770166)
15. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohns disease. N Engl J Med 2010;362:1383-95
16. Targan SR, Hanauer SB, van Deventer SJH, et al. for the Crohns disease cA2 study group. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohns disease. N Engl J Med 1997;337:1029-35
17. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohns disease: the CHARM trial. Gastroenterology 2007;132:52-65 (Pubitemid 46108762)
18. Colombel JF, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohns disease. Gut 2009;58:940-8
19. Ho GT, Smith L, Aitken S, et al. The use of adalimumab in the management of refractory Crohns disease. Aliment Pharmacol Ther 2008;27:308-15
20. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. for the PRECISE 2 Study Investigators. Maintenance therapy with certolizumab pegol for Crohns disease. N Engl J Med 2007;357:239-50 (Pubitemid 47080388)
21. Schreiber S, Rutgeerts P, Fedorak RN, et al. for the CDP870 Crohnss Disease Study Group. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohns disease. Gastroenterology 2005;129:807-18 (Pubitemid 41242673)
22. Remicade: Package Insert. Malvern, PA: Centocor Ortho Biotech, Inc. 2010
23. Humira: Package Insert. North Chicago, IL: Abbott Laboratories; 2009
24. Cimzia: Package Insert. Smyrna, GA: UCB, Inc.; 2009
25. Suarez D, Haro JM, Novick D, et al. Reasons and outcomes of olanzapine dose adjustments in the outpatient treatment of schizophrenia. Pharmacopsychiatry 2009;42:135-40
26. Waters H, Meekins T, Bewtra A, et al. Real-world dosing of anti-tumor necrosis factor therapies in the treatment of adults with Crohns disease. J Manag Care Pharm 2008;14:691
27. Nair KV, Tang B, Van Den Bos J, et al. Categorization of infliximab dose changes and healthcare utilization and expenditures for patients with rheumatoid arthritis in commercially insured and Medicare-eligible populations. Curr Med Res Opin 2009;25:303-14
28. Lindsay J, Punekar YS, Morris J, et al. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohns disease-modelling outcomes in active luminal and fistulizing disease in adults. Aliment Pharmacol Ther 2008;28:76-87 (Pubitemid 351782815)
29. Stein DJ, Ananthakrishnan AN, Issa M, et al. Impact of prior irregular infliximab dosing on performance of long-term infliximab maintenance therapy in Crohns disease. Inflamm Bowel Dis 2010; published online 18 November 2009, doi:10.1002/ibd.21164
30. Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohns disease. Gastroenterology 2005;128:862-9 (Pubitemid 40523539)
31. Taxonera C, Rodrigo L, Casellas F, et al. Infliximab maintenance therapy is associated with decreases in direct resource use in patients with luminal or fistulizing Crohns disease. J Clin Gastroenterol 2009;43:950-6